|
|
 |
|
Viewing report
|
|
|
|
The Top 10 Biotechnology Companies
Business Insights, Aug 2005
The top biotechnology companies are expected to continue outpacing the overall growth of the pharmaceutical market in the next 5 years, and prospects for long-term success have never been greater. The leading biotechnology companies are evolving into integrated companies, retaining ownership of their developmental compounds and building in-house sales and marketing functions.
'The Top 10 Biotechnology Companies' is a new management report which provides a detailed analysis of the 10 leading biotechnology companies and how they are planning to sustain growth over the next five years. For each company this report analyzes current and future therapeutic focus, sales growth, key pipeline products and how they are positioned for future growth.
The Top Ten Biotechnology Companies analyzed in this report are:
1. Amgen
2. Genentech
3. Serono
4. Biogen Idec
5. UCB-Celltech
6. Genzyme
7. Gilead
8. MedImmune
9. Chiron
10. Millennium
This new report will help you to identify the critical success factors that have driven company growth, evaluate diversification opportunities and assess the future potential of each company's R&D portfolio over the next five years.
Key questions answered in this report
- What market shares do the top 10 biotechs hold in the global biotechnology market?
- What are the major strengths, weaknesses, opportunities and threats for the top 10?
- Which companies in the top 10 are growing the fastest, and which are performing worst and why?
- What are the main problems encountered by biotechs on their way to achieving growth and profitability?
- Which companies are most active in licensing and alliance activity, and are these licensing/alliances with large pharmaceutical firms or with small biotech players?
- Which of the top 10 biotechs have the most promising drug pipelines for the future?
Reasons to read this report
- Tailor the best practice strategies of the biotech industry's global giants, to your company's needs, by reviewing detailed profiles of current and future drug portfolio's, growth strategies and organizational structure.
- Assess the pipeline strength of the top 10 biotechs companies and identify possible in-licensing or out-licensing opportunities.
- Turn your competitor's weaknesses into your strengths and gain a competitive edge through in-depth analysis the top 10 companies.
- Understand how the strategies of the leading integrated biotechs differ from emerging top-tier biotechs and identify the critical success factors for both types of strategies
- Identify which therapy areas offer the greatest opportunity for your company by evaluating the therapeutic focus of your competitors.
Customers who bought this item also bought
Biogen Idec: Pharmavitae Profile 2005
Biogen-IDEC: PharmaVitae Profile 2005
PharmaVitae 2003: Biogen-idec
PharmaVitae 2004: Biogen-IDEC Global & US Analysis
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
PharmaVitae 2004: Biogen-IDEC Global Analysis
UCB: Pharmavitae Profile 2005
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Therapeutic Monoclonal Antibodies Markets
Pharmavitae 2005: Chiron Global Analysis
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
|
|
|
|
